Study into molecular targets of a neuroprotective compound dimebon using a transgenic mice line

   


1. Institute of Physiologically Active Compounds of Russian Academy of Sciences
2. Orekhovich Institute of Biomedical Chemistry of the Russian Academy of Medical Sciences
3. Institute of Physiologically Active Compounds of Russian Academy of Sciences, Cardiff University, BIOSI3
Type: Experimental study
DOI: 10.18097/pbmc20146003354      UDK: 577.29      PubMed Id: 25019398
Year: 2014 vol: 60  issue:3  pages: 354-363
Abstract: In the present study we have used a transgenic mice overexpressing an amyloidogenic protein, gamma-synuclein, in the nervous system to address the effect of dimebon on proteinopathy progression. Neuroprotective effect of chronic dimebon administration in these mice at organismal level was confirmed by the increased lifespan. Using histological and biochemical approaches we have demonstrated that dimebon reduced the number of amyloid inclusions in spinal cord of transgenic animals and decreased the content of ubiquitinated proteins in detergent-insoluble fractions. These effects are likely to occur at the level of aggregated protein species, since transgene expression was not altered. Thus, pathological protein aggregation serves as one of dimebon targets in neurodegeneration.
Download PDF:
Reference: Shelkovnikova T.A., Ustyugov A.A., Kokhan V.S., Tarasova T.V., Medvedeva V.K., Khrytankova I.V., Bachurin S.O., Ninkina N.N., Study into molecular targets of a neuroprotective compound dimebon using a transgenic mice line, Biomeditsinskaya khimiya, 2014, vol: 60(3), 354-363.
This paper is also available as the English translation:10.1134/S1990750813020091
Bibliography
 2016(Vol:62)
 2015(Vol:61)
 2014(Vol:60)
 2013(Vol:59)
 2012(Vol:58)
 2011(Vol:57)
 2010(Vol:56)
 2009(Vol:55)
 2008(Vol:54)
 2007(Vol:53)
 2006(Vol:52)
 2005(Vol:51)
 2004(Vol:50)
 2003(Vol:49)